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Aims: EA‐230 is a human chorionic gonadotropin hormone‐derived linear
tetrapeptide, developed for the treatment of systemic inflammation‐related disorders.
EA‐230 has shown promising immunomodulatory and tissue‐protective effects in
animals and an excellent safety profile in human phase I studies that we performed.
The present phase IIa study follows‐up on these results by investigating the safety,
efficacy and pharmacokinetics of EA‐230 under systemic inflammatory conditions
induced by experimental human endotoxaemia.
Methods: In this randomized, double blind, placebo‐controlled phase IIa study,
systemic inflammation was induced by intravenous administration of Escherichia
coli‐derived lipopolysaccharide (LPS). At t = 0 hours, 36 healthy male volunteers
received 2 ng/kg LPS, followed by a 2‐hour continuous infusion of EA‐230 (15, 45
and 90 mg/kg/h, n = 8 per group) or placebo (n = 12).
Results: EA‐230 was well tolerated and showed a favourable safety profile. Treat-
ment with the highest dose of EA‐230 resulted in a significant attenuation of the
LPS‐induced increase in plasma levels of inflammatory mediators interleukin (IL)‐6, IL‐
8, IL‐1 receptor antagonist, monocyte chemoattractant protein‐1, macrophage inflam-
matory proteins‐1α and ‐1β, and vascular cell adhesion protein‐1 (% reduction of 48,
28, 33, 28, 14, 16 and 19 respectively, p < .01), and reduced fever (peak decrease from
1.8 ± 0.1°C to 1.3 ± 0.2°C, P < .05) and symptom scores (peak decrease from7.4 ± 1.0 to
4.0 ± 1.2 points, P < .05). EA‐230 exhibited a very short elimination half‐life and a large
volume of distribution in the highest dosage group (geometric mean and 95%
confidence interval: 0.17 [0.12–0.24] hours and 2.2 [1.3–3.8] L/kg, respectively).
Conclusion: Administration of EA‐230 is safe and results in attenuation of the
systemic inflammatory response in humans.
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs License, which permits use and distribution in any
medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
© 2019 The Authors. British Journal of Clinical Pharmacology published by John Wiley & Sons Ltd on behalf of British Pharmacological Society.
Trial registration: www.clinicaltrial.gov, NCT02629874
The authors confirm that the PI for this paper is Peter Pickkers and that he had direct clinical responsibility for the study participants.
Received: 26 July 2018 Revised: 28 February 2019 Accepted: 8 March 2019
DOI: 10.1111/bcp.13941
Br J Clin Pharmacol. 2019;85:1559–1571. wileyonlinelibrary.com/journal/bcp 1559
KEYWORDS
cytokines, drug safety, immunotherapy, inflammation, pharmacokinetics
1 | INTRODUCTION
Systemic inflammation can arise due to a variety of infectious as well
as non‐infectious conditions such as sepsis, trauma and major surgical
interventions.1,2 Although the immune response is essential for clear-
ance of pathogens and initiation of tissue repair, a too persistent or
overzealous response is detrimental and can lead to pronounced
tissue damage with associated organ failure and mortality rates up to
30%.3,4 This is for instance exemplified by the high incidence of acute
kidney injury (AKI) in systemic inflammation‐related conditions, occur-
ring in over a half of critically ill patients and in up to 30% of patients
undergoing elective cardiac surgery.5-8
Despite its tremendous impact, no immunomodulatory interven-
tions have proven to be effective in regulating the systemic inflamma-
tory response to prevent organ injury.9-11 Current strategies are
confined to supportive treatment and novel strategies aimed at
attenuating this exaggerated inflammatory response to prevent organ
failure are therefore highly warranted.
EA‐230 is a synthetic linear tetrapeptide (alanine–glutamine–gly-
cine–valine; AQGV) derived from the β‐chain of the human chorionic
gonadotropin hormone (β‐HCG). The discovery of this peptide finds
its roots in the unique immunological situation encountered during
pregnancy, in which the maternal immune system is adapted to toler-
ate the semi‐allogeneic fetus without compromising pathogen clearing
capacity.12,13 A striking hallmark of this immune‐tolerant phenotype is
attenuated disease activity of various autoimmune diseases such as
rheumatoid arthritis, multiple sclerosis and psoriasis during pregnancy
and their relapse after delivery.14-17 HCG was shown to play a central
role in this immune‐tolerant adaption of the maternal immune sys-
tem,18-21 which has led to the discovery of immune active fragments
of the β‐chain. These oligopeptides were found to circulate abundantly
throughout pregnancy and to exert beneficial effects in various animals
models of systemic inflammation, including attenuation of the inflam-
matory response, less organ failure and improved survival.22-31 Of
these peptides, the linear tetrapeptide AQGV (later named EA‐230)
strongly attenuated inflammation, preserved kidney function, and
substantially reduced mortality in models of renal ischaemia–
reperfusion,24 kidney transplantation,25 and haemorrhagic‐28 and
endotoxaemia‐induced shock.26
Following these encouraging preclinical results, we performed
phase I studies with different dosing regimens that showed EA‐230
to be well‐tolerated with an excellent safety profile (reported else-
where in this issue32).
The present phase IIa study follows‐up on our earlier results. In a
randomized, double‐blind, placebo‐controlled study, we investigated
the safety, efficacy and pharmacokinetics of EA‐230 during experimen-
tal human endotoxaemia, a standardized controlled model of systemic
inflammation induced by intravenous administration of Escherichia coli‐
derived lipopolysaccharide (LPS) to healthy volunteers.
2 | MATERIALS AND METHODS
2.1 | Subjects, ethics and study design
Following written informed consent, 36 healthy adult males were
enrolled in this single‐centre, double‐blind, randomized, placebo‐
controlled phase IIa study. The study protocol was approved by the
local ethics committee (CMO Arnhem‐Nijmegen, NL56102.091.15;
2015–2231) and was prospectively registered at clinicaltrial.gov
(NCT02629874). All study procedures complied with the Declaration
of Helsinki, including current revisions, and Good Clinical Practice
standards. Quality assurance, full data validation and monitoring of
all source documents and study procedures were performed by a
contract research organization (QPS, Groningen, the Netherlands).
Health status of the participants was determined by medical
history, physical examination, electrocardiogram (ECG) and routine
laboratory blood tests. Exclusion criteria included body mass index
<18 or >30 kg/m2, clinically significant illness within 2 weeks before
the start of the study, known hypersensitivity to any excipients of
What is already known about this subject
• EA‐230 is a β‐hCG‐derived immunomodulatory
tetrapeptide, developed for the treatment of systemic
inflammation‐related disorders.
• EA‐230 was shown to reduce organ dysfunction and
mortality in various animal studies of systemic
inflammation.
• Phase I studies showed an excellent safety profile of EA‐
230 and pharmacokinetics analysis revealed a very short
half‐life and a large volume of distribution.
What this study adds
• No safety issues emerged in this phase IIa study in 36
volunteers.
• EA‐230 attenuates the systemic inflammatory response in
humans in vivo.
• Results of this study provide the basis for a patient study
with EA‐230.
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the drug formulations used, history of spontaneous vagal collapse,
significant blood loss within 90 days prior to the study, participation
in any other clinical trial within 1 month prior to the study and par-
ticipation in a previous trial in which LPS was administered. Prior to
and during every study procedure, subjects were not allowed to use
any medication, recreational drugs, nicotine, caffeine and/or alcohol.
Subjects were consecutively assigned to the 15, 45 or 90 mg/kg/h
group, based on the order of their appearance on the study drug
administration day. Dose regimens were based on the phase I studies
using the same dosages without any safety concerns reported else-
where in this issue.32 Each dosage group consisted of 12 subjects;
within each dosage group subjects were randomly assigned to
receive either EA‐230 or placebo (n = 8 active study drug, n = 4
placebo) making use of a randomization list. All subjects underwent
endotoxaemia in combination with EA‐230 or placebo, as further
detailed below.
The primary endpoint was safety and tolerability, assessed by the
incidence of treatment related (serious) adverse events ([S]AEs).
Secondary endpoints included effects on the LPS‐induced inflamma-
tory response and pharmacokinetics.
2.2 | Study medication
EA‐230 and placebo were supplied as solution for injection in identi-
cal 5 mL sterile single‐use vials. EA‐230 vials contained 300 mg/mL
active substrate and placebo vials contained an osmolar equivalent
of 29 mg/mL sodium chloride solution. Vials were manufactured by
Halix BV (Leiden, Netherlands), quality controlled by PROXY
Laboratories BV (Leiden, Netherlands), vials with EA‐230 were stored
at 2–8°C and placebo vials at room temperature. Before administra-
tion, the required dosage of EA‐230 or placebo was diluted in 0.9%
NaCl to a volume of 500 mL. Manufacturing, packaging, quality con-
trol and preparation were described in an Investigational Medicinal
Product Dossier and complied with Good Manufacturing Practice
requirements.
2.3 | Study procedures and experimental human
endotoxaemia
A schematic overview of the study procedures is depicted in Figure 1.
Study subjects were administered to a fully equipped research unit
at the intensive care unit of the Radboud university medical centre.
The nondominant arm was cannulated for intravenous (i.v.) fluid
administration and a 20‐gauge arterial catheter was used for continu-
ous blood pressure monitoring and blood sampling. As part of our
standard endotoxaemia protocol,33-35 subjects received a 1‐hour infu-
sion of 1.5 L prehydration solution (2.5% glucose/4.5% NaCl) starting
at t = −1 h. At t = 0 h, LPS was administered, the intravenous cannula
was flushed with 0.9% NaCl, and study drug treatment was initiated.
Purified LPS (US Standard Reference Endotoxin Escherichia coli
O:113) obtained from the Pharmaceutical Development Section of
the National Institutes of Health (Bethesda, MD, USA) was adminis-
tered as an i.v. bolus injection at a dose of 2 ng/kg body weight. Study
drug treatment was administered as a 2‐hour continuous i.v. infusion
at 250 mL/h. Fluid administration continued at t = 2 h, after cessation
of study drug treatment, at 150 mL/h. During the day frequent blood
samples were collected and adverse events, vital signs and
endotoxaemia‐related symptoms were monitored until discharge at
t = 8 h. Subjects returned at 24 hours, 48 hours, 7 days and 14 days
after study drug administration for follow‐up.
2.4 | Safety
Safety and tolerability assessments were performed continuously
from the start of study drug treatment until 8 hours afterwards and
at 4 consecutive study visits during the 14‐day follow‐up period.
Safety parameters included vital signs (blood pressure and heart rate),
12‐lead ECG and routine laboratory haematology and biochemistry.
AEs were recorded throughout the complete study period. All AEs
were judged by the investigator with regard to severity (mild, moder-
ate or severe) according to CommonTerminology Criteria for Adverse
Events guidelines 4.0,36 and their relation to the study drug (definitely
FIGURE 1 Schematic overview of study procedures. Time points on the horizontal axes are in hours relative to LPS administration unless
specified otherwise. ICU: intensive care unit; LPS: lipopolysaccharide; (S)AEs: (serious) adverse events; h: hours; d: days
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related, probably related, possibly related, unlikely to be related or
unrelated). LPS‐induced flu‐like symptoms were scored separately,
as explained below, and for practical considerations excluded from
safety analyses. SAEs included death, life‐threatening, persistent
and/or significant disability and/or incapacity and hospitalization
and/or prolongation of inpatient hospitalization. Safety parameters
were reported to and reviewed by an independent Data Safety Mon-
itoring Board (DSMB) after completion of each dosing group.
2.5 | Plasma inflammatory mediators
Ethylenediaminetetraacetic acid (EDTA)‐anticoagulated blood samples
for measurement of inflammatory parameters were obtained at time
points t = 0, 0.5, 1, 1.5, 2, 3, 4, 6 and 8 hours (Figure 1). Samples were
immediately centrifuged at 2000 g for 10 minutes at 4°C after which
plasma was stored at −80°C until analysis. Plasma levels of a core
set of inflammatory mediators (interleukin [IL]‐6, IL‐10 and tumour
necrosis factor [TNF]‐α), were determined using a validated,
ISO9001 certified multiplex immunoassay technology (Luminex,
Austin, TX, USA) at the Laboratory of Translational Immunology of
the University Medical Center Utrecht as described elsewhere.37
Plasma levels of IL‐8, monocyte chemoattractant protein (MCP)‐1,
IL‐1 receptor antagonist (RA), macrophage inflammatory protein
(MIP)‐1α and MIP‐1β were determined using a Luminex assay accord-
ing to the manufacturer's instructions (Milliplex; Merck Millipore,
Billerica, MA, USA). Plasma levels of endothelial adhesion proteins
intercellular adhesion molecule (ICAM)‐1 and vascular cell adhesion
protein (VCAM)‐1 were also analysed using a Luminex assay (Bio‐plex;
Bio‐Rad, Hercules, CA, USA) according to manufacturer's instructions.
2.6 | Leucocyte counts and differentiation
EDTA anticoagulated blood samples were obtained at time points
t = −1, 0, 1, 2, 4, 8, 24 and 48 hours (Figure 1). Direct measurements
of leucocyte counts and differentiations were performed using clinical
routine analysis methods at the Laboratory of Clinical Chemistry of
the Radboud university medical center (Sysmex XE‐5000, Sysmex
Nederland B.V., Etten‐Leur, the Netherlands).
2.7 | Vital signs and endotoxaemia‐induced
symptoms
Heart rate, measured with a 3‐lead ECG, and blood pressure were
recorded every 30 seconds from a Philips MP50 patient monitor using
an in‐house developed system. Every 30 minutes, temperature was
measured using an infrared tympanic thermometer (First‐Temp Genius
2; Covidien, Dublin, Ireland), and LPS‐induced flu‐like symptoms
(headache, nausea, shivering, muscle and back pain) were scored per
symptom (0 = no symptoms, 5 = worst ever experienced, vomiting:
additional 3 points), resulting in a total symptom score of 0–28.
2.8 | Pharmacokinetics
Blood samples for measurement of EA‐230 concentrations were
obtained at time points t = 0, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8 and 24 hours
(Figure 1). Protease Inhibitor Cocktail (300 μL, P8340; Sigma‐Aldrich
Chemie, Zwijndrecht, The Netherlands) was added immediately after
withdrawal of 3 mL EDTA‐anticoagulated blood to prevent proteolytic
degradation of EA‐230. Hereafter, blood samples were centrifuged at
2000 g for 15 minutes at 4°C and plasma samples were stored at
−80°C until analysis. EA‐230 concentrations were determined by a
validated liquid chromatography tandem mass spectrometry assay as
described elsewhere in this issue.32 The detection range of the
method was 0.5–100 ng/mL with low, medium and high quality
control concentrations of 1.5, 10 and 75 ng/mL.
Pharmacokinetic analysis was performed with non‐compartmental
methods using WinNonLin/Phoenix version 6.3 (Pharsight Corpora-
tion, USA). The highest observed plasma concentration was defined
as Cmax. The area under the plasma vs concentration time curve from
t = 0 to the time of the last measured concentration (AUC0‐last) was
calculated using the linear‐log trapezoidal rule, with extrapolation to
infinity (using Clast/β) to obtain the AUC from t = 0 to infinity
(AUC0‐inf). The log‐linear period (log concentration vs time) was
defined by visual inspection of data points. The absolute value of
the slope (β/2.303) was calculated by least squares linear regression
analysis, where β is the first‐order elimination rate constant. Elimina-
tion half‐life (t1/2) was calculated by the equation 0.693/β. Clearance
(Cl) was calculated by dividing dose by AUC0‐inf and volume of distri-
bution (Vd) by dividing Cl by β.
2.9 | Statistical analysis
The study was regarded as exploratory in nature and sample size was
based on practical considerations, exposing a limited number of sub-
jects while obtaining the necessary safety and efficacy data. (S)AEs
are summarized by treatment group, preferred term, severity and
relation to the study drug. Efficacy data are presented as mean ± stan-
dard error of the mean, demographic data as mean ± standard devia-
tion. PK parameters are presented as geometric mean and 95%
confidence interval. Data were tested for normality using the
Shapiro–Wilk test and a maximum normalized residual test according
to Grubb was performed on efficacy data to identify significant out-
liers with a P < .01. Differences over time between EA‐230‐treated
and placebo‐treated subjects were compared by repeated measures
2‐way ANOVA (interaction term: group*time). Baseline differences
in demographic data were tested using a 1‐way ANOVA. Dose
proportionality of dose vs AUC0‐last, and Cmax was assessed using
1‐way ANOVA followed by a Bonferroni posthoc test on dose‐
normalized, log‐transformed data.
All statistical analyses were performed using GraphPad Prism ver-
sion 5.03 (GraphPad Software, San Diego, CA, USA). A 2‐sided P‐value
<.05 was considered statistically significant.
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3 | RESULTS
3.1 | Baseline characteristics and subject disposition
All study subjects received study medication according to the protocol
and there were no relevant baseline differences between groups
(Table 1). One subject in the 90 mg/kg/h group was excluded from
all efficacy analyses because of an unusually high cytokine response
(significant outlier both within the 90 mg/kg/h group and in all groups
combined for IL‐6 and TNF‐α [Grubb's test P < .01]) in combination
with gastrointestinal complaints that were assessed as unlikely to be
related to the study drug or endotoxin administration.
3.2 | Safety
A summary of all (S)AEs with severity and relation to the study treat-
ment are listed inTable 2A and their preferred terms are organized per
system organ class in Table 2B.
No SAEs were reported and infusion of EA‐230 during experimen-
tal endotoxaemia was well‐tolerated by all subjects across dosage
groups without any safety concerns and/or discontinuation of study
drug administration. Accordingly, no concerns were raised by the
DSMB after completion of each dosing group.
Nineteen AEs were reported by 14 subjects, all of which were mild,
transient and considered not, or unlikely to be, related to study drug
treatment. Seven subjects (29%) treated with EA‐230 and seven
placebo‐treated subjects (58%) reported ≥1 AE. Of all AEs, 9 were
reported in the placebo group vs 10 in EA‐230 treated subjects, 5 of
which in the highest dosing group.
Other than the expected LPS‐induced alterations in vital signs and
leucocyte counts discussed below, alterations in laboratory parame-
ters, vital signs and 12‐leads ECG were considered not clinically
significant.
3.3 | Effects of EA‐230 on circulating levels of
inflammatory mediators and adhesion molecules
during endotoxaemia
The LPS‐induced increase in plasma levels of inflammatory cytokines
IL‐6 and IL‐1RA was significantly attenuated in subjects treated with
TABLE 1 Demographic characteristics
Placebo 15 mg/kg/h 45 mg/kg/h 90 mg/kg/h
(n = 12) EA‐230 (n = 8) EA‐230 (n = 8) EA‐230 (n = 8) P‐value
Age, y 23 ± 3 22 ± 1 22 ± 3 22 ± 2 .62
BMI, kg/m2 23.2 ± 2.5 23.0 ± 1.7 22.7 ± 2.9 23.1 ± 2.7 .98
Weight, kg 77 ± 8 78 ± 7 72 ± 9 79 ± 16 .53
Height, cm 183 ± 5 184 ± 4 178 ± 8 184 ± 11 .27
HR, beats/min 64 ± 9 65 ± 9 62 ± 7 67 ± 8 .69
MAP, mmHG 95 ± 11 94 ± 3 92 ± 4 91 ± 6 .71
Parameters were determined during screening visit. BMI: body mass index; HR: heart rate; MAP: mean arterial pressure. Data are presented as mean ± stan-
dard deviation. P‐values were calculated using 1‐way ANOVA.
TABLE 2A Summary of adverse events
Placebo
(n = 12)
15 mg/kg/h
EA‐230 (n = 8)
45 mg/kg/h
EA‐230 (n = 8)
90 mg/kg/h
EA‐230 (n = 8)
Overall
(n = 36)
n (%) n (%) n (%) n (%) n (%)
Any AE 7 (58.3) 2 (25.0) 2 (25.0) 3 (37.5) 14 (38.9)
Any serious AE 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Discontinued due to AE 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Concomitant medication given 0 (0.0) 0 (0.0) 1 (12.5) 0 (0.0) 1 (2.8)
AE of mild intensity 7 (58.3) 2 (25.0) 2 (25.0) 3 (37.5) 14 (38.9)
AE of moderate intensity 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
AE of severe intensity 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Definitely related AE 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Probably related AE 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Possibly related AE 1 (8.3) 0 (0.0) 0 (0.0) 0 (0.0) 1 (2.8)
Unlikely related/unrelated AE 6 (50.0) 2 (25.0) 2 (25.0) 3 (37.5) 13 (36.1)
AE, adverse events; n, number of subjects.
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90 mg/kg/h EA‐230 compared to the placebo group (% reduction
in AUC of 48 and 33 respectively), but not of TNF‐α and IL‐10
(% increment in AUC of 1 and 33 respectively; Figure 2). The other
dosages of EA‐230 had no effects on either of these cytokines,
these data are depicted in Supplemental data file 1. Treatment
with the highest dose of EA‐230 also significantly attenuated circu-
lating levels of chemokines IL‐8, MCP‐1, MIP1‐α and MIP1‐β
(% reduction in AUC of 28, 28, 14 and 16 respectively; Figure 3),
and plasma concentrations of the endothelial adhesion molecule
VCAM‐1, but not intercellular adhesion molecule‐1 (% reduction in
AUC of 19 and 5 respectively; Figure 4). Again, the lower dosages
of EA‐230 had no effects on any of these mediators (Supplemental
data file 1).
3.4 | Effects of EA‐230 on leucocyte counts and
differentiation during endotoxaemia
LPS administration typically caused initial leucopenia during the 1st
hour followed by a profound increase in numbers of circulating
leucocytes (Figure 5A). Treatment with 90 mg/kg/h EA‐230 did not
affect the initial decrease in leucocyte counts, whereas it subsequently
resulted in higher leucocyte counts compared to the placebo group, an
effect mainly attributed to increased numbers of circulating
neutrophils and lymphocytes, but not monocytes (Figures 5). The
lower dosages of EA‐230 did not influence leucocyte numbers or
differentiation compared to the LPS‐response in the placebo group
(Supplemental data file 1).
3.5 | Effects of EA‐230 on vital signs and symptoms
during endotoxaemia
Endotoxaemia resulted in fever (approximately an increase in body
temperature of 2°C; Figure 6A), development of influenza‐like symp-
toms (Figure 6B), a decrease in mean arterial pressure (approximately
10 mmHg; Figure 6C), and an increase in heart rate (approximately
30 beats/min; Figure 6D). Fever peaked at 3–3.5 hours following
LPS administration and was significantly lower in subjects treated
with 90 mg/kg/h EA‐230 compared to placebo (increase of
1.3 ± 0.2°C vs. 1.8 ± 0.1°C, respectively, at t = 3.5; Figure 6A). Flu‐like
symptoms peaked at 1.5 hours after LPS administration and were
approximately halved in subjects treated with 90 mg/kg/h EA‐230
compared to placebo (4.0 ± 1.2 points vs. 7.4 ± 1.0 points respec-
tively; Figure 6B). The LPS‐induced effects on mean arterial pressure
and heart rate were not altered by EA‐230 in any of the dosages
(Supplemental data file 1).
TABLE 2B Summary of adverse events by system organ class and preferred term
Dosage groups
Placebo
(n = 12)
15 mg/kg/h
EA‐230
(n = 8)
45 mg/kg/h
EA‐230
(n = 8)
90 mg/kg/h
EA‐230
(n = 8)
Overall
(n = 36)
System organ class and preferred term n (%) e n (%) e n (%) e n (%) e n (%) e
Number of subjects with at least 1
adverse event
7 (58.3) 9 2 (25.0) 3 2 (25.0) 2 3 (37.5) 5 14 (38.9) 19
General disorders 4 (33.3) 5 1 (12.5) 1 0 (0.0) 0 1 (12.5) 1 6 (16.7) 7
‐ Infusion site reaction 4 (33.3) 4 1 (12.5) 1 0 (0.0) 0 1 (12.5) 1 6 (16.7) 6
‐ Feeling hot 1 (8.3) 1 0 (0.0) 0 0 (0.0) 0 0 (0.0) 0 1 (2.8) 1
Nervous system disorders 1 (8.3) 1 1 (12.5) 1 0 (0.0) 0 0 (0.0) 0 2 (5.6) 2
‐ Head discomfort 1 (8.3) 1 1 (12.5) 1 0 (0.0) 0 0 (0.0) 0 2 (5.6) 2
Gastrointestinal disorders 0 (0.0) 0 1 (12.5) 1 0 (0.0) 0 1 (12.5) 2 2 (5.6) 3
‐ Nausea 0 (0.0) 0 0 (0.0) 0 0 (0.0) 0 1 (12.5) 1 1 (2.8) 1
‐ Upper abdominal pain 0 (0.0) 0 0 (0.0) 0 0 (0.0) 0 1 (12.5) 1 1 (2.8) 1
‐ Soft faeces 0 (0.0) 0 1 (12.5) 1 0 (0.0) 0 0 (0.0) 0 1 (2.8) 1
Musculoskeletal disorders 1 (8.3) 1 0 (0.0) 0 2 (25.0) 2 2 (25.0) 2 5 (13.9) 5
‐ Pain in extremity 0 (0.0) 0 0 (0.0) 0 1 (12.5) 1 2 (25.0) 2 3 (8.3) 3
‐ Back pain 0 (0.0) 0 0 (0.0) 0 1 (12.5) 1 0 (0.0) 0 1 (2.8) 1
‐ Muscular weakness 1 (8.3) 1 0 (0.0) 0 0 (0.0) 0 0 (0.0) 0 1 (2.8) 1
Respiratory disorders 1 (8.3) 1 0 (0.0) 0 0 (0.0) 0 0 (0.0) 0 1 (2.8) 1
‐ Rhinorrhoea 1 (8.3) 1 0 (0.0) 0 0 (0.0) 0 0 (0.0) 0 1 (2.8) 1
Infectious disorders 1 (8.3) 1 0 (0.0) 0 0 (0.0) 0 0 (0.0) 0 1 (2.8) 1
‐ Tonsillitis 1 (8.3) 1 0 (0.0) 0 0 (0.0) 0 0 (0.0) 0 1 (2.8) 1
AE, adverse events; e, number of events; n, number of subjects.
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3.6 | Pharmacokinetics of EA‐230 during
endotoxaemia
Plasma EA‐230 concentration–time profiles and dose linearity are
illustrated in Figure 7. PK parameters are summarized in Table 3.
Figure 7A illustrates that stable plasma concentrations were reached
for all dosage groups within 15 minutes after start of study treatment
and during the 2‐hour continuous administration period, followed by a
very rapid decline in plasma concentrations after cessation of study
treatment. Due to this very swift decline, the elimination rate constant
β (and t1/2, Cl and Vd) could only be calculated in a limited number of
subjects for the first 2 dosage groups (15 and 45 mg/kg/h). These
analyses revealed rapid plasma elimination, with a t1/2 of <0.77 h in
the 15 mg/k/h group (n = 3) and <0.16 h in the 45 mg/kg/h (n = 5).
In the highest dosing group, β could be estimated for all 8 subjects,
and a large volume of distribution (range: 1.3–3.8 L/kg), a short elimi-
nation t1/2 (range: 0.12–0.24 h) and a corresponding rapid clearance
rate (range: 7–12 L/h/kg) for EA‐230 was apparent. The dosage
increase from 15 mg/kg/h to 90 mg/kg/h resulted in proportional
increases in Cmax and AUC0‐last (Figure 7B–C, Table 3).
4 | DISCUSSION
In this double‐blind, placebo‐controlled phase IIa study, we studied
the safety and immunomodulatory effects of the β‐HCG derived
peptide EA‐230 in healthy volunteers during experimental
endotoxaemia. Our data demonstrate that EA‐230 profoundly attenu-
ates the systemic inflammatory response in humans in vivo. Further-
more, we show that EA‐230 is well‐tolerated and seems to be safe
for administration under inflammatory conditions.
A 2‐hour infusion of EA‐230 in the highest tested dosage of
90 mg/kg/h dampened the endotoxin‐induced proinflammatory innate
immune response, exemplified by attenuated plasma levels of the pro-
inflammatory cytokine IL‐6, chemokines IL‐8, MCP‐1, MIP‐1a and
MIP‐1b, and endothelial adhesion molecule VCAM‐1. Levels of the
archetypal anti‐inflammatory cytokine IL‐10 were not affected by
the study drug. In addition to these biochemical findings, modulation
of the inflammatory response by EA‐230 was supported clinically by
a significant reduction in endotoxin‐induced fever and influenza‐like
symptoms. These findings are in line with preclinical studies that dem-
onstrated that EA‐230 attenuates cytokine production, prevents tis-
sue influx of neutrophils24,26,28 and ameliorates inflammation‐related
clinical symptoms24-26,28 in various models of systemic inflammation.
Our data also reveal that, following the expected LPS‐induced initial
leucopenia (predominantly mediated by endothelial sequestration of
lymphocytes and monocytes), the subsequent increase in numbers of
circulating leucocytes (predominantly due to increased neutrophil
numbers released from the bone marrow) was more pronounced in
EA‐230‐treated subjects.
The substantial attenuation of the endotoxaemia‐induced IL‐6
response in EA‐230‐treated subjects may be of clinical relevance, as
FIGURE 2 Plasma levels of cytokines during endotoxaemia. A, Interleukin (IL)‐6, B, IL‐1 receptor antagonist (RA), C, tumour necrosis factor
(TNF)‐α, D, IL‐10. Data are represented as means with standard error of the mean of n = 7 in the EA‐230 90 mg/kg/h group and n = 12 in the
placebo group. Grey box indicates the period in which the active group received EA‐230. P‐values between groups were calculated using repeated
measures 2‐way analysis of variance (ANOVA, interaction term)
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IL‐6 is implicated to play a central role in various inflammatory
disorders. As such, this cytokine is regarded to be a reliable marker
reflecting the magnitude of systemic inflammation, e.g. following
elective surgery38 or in patients with pneumonia.39 Furthermore, IL‐
6 levels are associated with organ failure and impaired (functional)
outcome following severe injury,40 cardiac surgery,41 cardiac arrest,42
stroke43 and sepsis.44 With respect to renal function, IL‐6 plays a
critical role in the development of AKI,45 independently predicting
mortality in patients starting dialysis46 and predicting AKI following
cardiac surgery.41 In this perspective, our results are promising and
EA‐230 may show efficacy on these clinical endpoints in future
studies.
Administration of EA‐230 was well‐tolerated throughout the
conduct of the trial and no safety issues were raised during frequent
independent interim safety analyses by the DSMB and in the final
results. No dose‐dependency for adverse events was observed and
FIGURE 3 Plasma levels of chemokines during endotoxaemia. A, Interleukin (IL)‐8, B, monocyte chemoattractant protein (MCP)‐1,
C, macrophage inflammatory protein (MIP)‐1α D, MIP‐1β. Data are represented as means with standard error of the mean of n = 7 in the
EA‐230 90 mg/kg/h group and n = 12 in the placebo group. Grey box indicates the period in which the active group received EA‐230. P‐values
between groups were calculated using repeated measures 2‐way analysis of variance (ANOVA, interaction term)
FIGURE 4 Plasma levels of endothelial cell adhesion molecules during endotoxaemia. A, Vascular cell adhesion molecule (vCAM)‐1;
B, intercellular adhesion molecule (iCAM)‐1. Data are represented as means with standard error of the mean of n = 7 in the EA‐230 90 mg/kg/h
group and n = 12 in the placebo group. Grey box indicates the period in which the active group received EA‐230. P‐values between groups were
calculated using repeated measures 2‐way analysis of variance (ANOVA, interaction term)
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FIGURE 5 Circulating leucocyte numbers during endotoxaemia. A, Leucocytes, B, neutrophils, C, lymphocytes, D, monocytes. Data are
represented as means with standard error of the mean of n = 7 in the EA‐230 90 mg/kg/h group and n = 12 in the placebo group. Grey box
indicates the period in which the active group received EA‐230. P‐values between groups were calculated using repeated measures 2‐way analysis
of variance (ANOVA, interaction term)
FIGURE 6 Clinical variables during endotoxaemia. A, Increase in body temperature B, symptom scores, C, mean arterial pressure, D, heart rate.
Data are represented as means with standard error of the mean of n = 7 in the EA‐230 90 mg/kg/h group and n = 12 in the placebo group. Grey
box indicates the period in which the active group received EA‐230. P‐values between groups were calculated using repeated measures 2‐way
analysis of variance (ANOVA, interaction term). AU: arbitrary unit; Bpm: beats/min
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the percentage of subjects with 1 or more AE tended to be less com-
mon in the highest dosing group compared to the placebo group
(respectively 58 vs 38%). Furthermore, all AEs in the active groups
were of mild intensity and regarded unlikely or unrelated to study drug
treatment. These results are consistent with earlier human phase I tri-
als focusing on safety of EA‐230 in the absence of systemic inflamma-
tion reported elsewhere in this issue32 and indicate that EA‐230
seems to be safe in dosages up to 90 mg/kg/h. Further safety data
with higher dosages and/or longer administration duration would be
needed to study a possible exposure‐dependent effect.
One subject was found to be a statistically significant outlier (per
Grubb's test) and was excluded for the primary efficacy analyses.
When this volunteer was not excluded, the effects of EA‐230 on
clinical endpoints remained statistically significant, while the effects
on some of the cytokines went from statistically significant to a trend.
Data on the pharmacokinetic profile of EA‐230 reveal a large volume
of distribution, a very rapid systemic clearance and accordingly a short
half‐life. A finding of interest is the substantially higher plasma concen-
trations of EA‐230 compared to the phase I continuous dosing study
reported elsewhere in this issue,32 which was performed and analysed
within the same institute, using exactly the same dosing regimens (15,
45 and 90mg/kg/h for 2‐hours). The elimination rates (β) were, however,
comparable to those found in the phase I continuous dosage study. The
observed increase in plasma concentrations are therefore accompanied
FIGURE 7 Pharmacokinetics of EA‐230. A, Plasma concentration‐time profiles of EA‐230. The grey area indicates the study drug administration
period. B, C, Dose proportionality of dose‐normalized, log‐transformed exposure parameters Cmax (B), and AUC0‐last (C). Linear regression lines are
shown, dotted lines indicate the 95% confidence interval, a P‐value of <.05 would have indicated nonproportionality. Data are expressed as
geometric means and 95% confidence interval
TABLE 3 Pharmacokinetic parameters of EA‐230
Pharmacokinetic parameters n
15 mg/kg/h
EA‐230 n
45 mg/kg/h
EA‐230 n
90 mg/kg/h
EA‐230
AUC0‐last (h μg/L) 8 2672 (2097–3403) 8 7647 (5431–10766) 8 19658 (15428–25046)
AUC0‐inf (h μg/L) 3 3349 (1244–9014) 5 6519 (4243–10015) 8 19658 (15429–25046)
Cmax (μg/L) 8 1983 (1725–2279) 8 6030 (4190–8676) 8 15657 (13100–18714)
T1/2 (h) 3 0.15 (0.03–0.77) 5 0.11 (0.08–0.16) 8 0.17 (0.12–0.24)
CL (L/h/kg) 3 9 (3–24) 5 14 (9–21) 8 9 (7–12)
Vd (L/kg) 3 1.9 (0.1–2.6) 5 2.3 (1.3–3.9) 8 2.2 (1.3–3.8)
Data expressed as geometric means and 95% CI. T1/2: elimination half‐life; Cmax: highest observed plasma concentration; AUC0‐last: the area under the
plasma vs concentration time curve from t = 0 to the time of the last measured concentration; AUC0‐inf: the area under the plasma vs concentration time
curve from t = 0 to infinity extrapolated; Cl: plasma clearance; Vd: volume of distribution.
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by a decrease in Vd and Cl. These findings indicate that LPS‐induced sys-
temic inflammation affected the pharmacokinetic behaviour of EA‐230
by decreasing the volume of distribution and increasing plasma concen-
tration of EA‐230. As the exact mode of action of EA‐230 still remain
to be elucidated, it is unclear by what mechanism(s) the inflammatory
response affects the PK of EA‐230. Receptor competition with an
inflammation‐dependent ligand or decreased internalization of EA‐230
during systemic inflammationmay bepossible explanations for the limita-
tion of the drug's volume of distribution and subsequent increase in
plasma concentrations. Taken together, the PK‐profile indicates that
EA‐230 distributes over a large volume and is very rapidly metabolized
with plasma clearance exceeding both renal and portal flow. This profile
is affected by systemic inflammation, as reflected by the observed poten-
tiated plasma concentrations and a lower volume of distribution during
experimental human endotoxaemia.
Several limitations of this study need to be addressed. The experi-
mental human endotoxaemia model elicits a predictable and reproduc-
ible systemic inflammatory response and therefore provides a suitable
model for a proof‐of‐principle study evaluating an immunomodulatory
compound. However, as with any model, it has several limitations. First,
LPS is a specific toll‐like receptor‐4 ligand and is administrated in a sin-
gle bolus. As such, it recapitulates a 1‐hit immunological insult activat-
ing a specific pathway, which may differ from the immune response
observed in clinical practice, which is often more sustained and caused
by various pathogens or other immunological insults activating multiple
pathways. Second, young healthy male subjects were included to min-
imize statistical dispersion, as age, female sex and comorbidities are
known factors accounting for heterogeneity in inflammatory
responses.47,48 This markedly differs from clinical practice, where dis-
eases associated with a systemic inflammatory response occur in peo-
ple of all ages, both sexes, and are frequently complicated by 1 or
more comorbidities as well as the use of comedication. Therefore, the
generalizability of our results to the patient population remains to be
determined. Third, although all PK parameters could be determined in
all subjects of the highest dosing group, the pharmacokinetic character-
istics of EA‐230 (e.g. its very short half‐life) precluded assessment of
elimination constant‐dependent parameters in several subjects of the
lower dosage groups. However, in these subjects, plasma concentra-
tions approaching zero (after approximately 5 timesT1/2) were reached
within an hour, suggesting aT1/2, of <0.2 h, which is in line with the data
obtained in subjects in whom elimination constant‐dependent parame-
ters could be assessed. Finally, the exact mechanism(s) by which EA‐
230 modulates the immune response remain unclear and may have
consequences for the optimal timing of administration. In the current
study, steady‐state concentrations EA‐230 were present during the
orchestration phase and peak (e.g. IL‐6) of the inflammatory response.
In clinical practice, the timing of the inflammatory insult(s) is/are gener-
ally unknown and a subsequent more diffuse and longer lasting inflam-
matory response is often observed. Therefore, no definite conclusions
regarding the optimal timing of administration of EA‐230 for future
clinical research can be drawn from this study.
In conclusion, the present proof‐of‐principle study demonstrates that
EA‐230 seems to be safe and attenuates the systemic inflammatory
response in humans. Substantially higher plasma concentrations of EA‐
230 were observed in subjects with systemic inflammation compared
to non‐inflamed subjects, which was explained by a decrease in volume
of distribution and clearance, but not by differences in the elimination
constant. These inflammation‐related effects on pharmacokinetic char-
acteristics of EA‐230 need to be further elucidated. The favourable
safety profile of EA‐230 and promising immunomodulatory results pave
the way for a phase IIb clinical trial to assess the anti‐inflammatory and
tissue‐protective effects of EA‐230 in patients.49
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